Catalyst Pharmaceuticals Inc
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
- Ticker
- CPRX
- Trading on
- NASDAQ
- ISIN
- US14888U1016
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Richard John Daly M.B.A.
- Headquarters
- 355 Alhambra Circle, Coral Gables, FL, United States, 33134
- Employees
- 182
- Website
- https://catalystpharma.com
Metrics
Analyst Insights & forecasts
Based on information from 7 analysts.
Earnings per share (EPS) forecast
| Q2 • 25 | Q3 • 25 | Q4 • 25 | Q1 • 26 | |
|---|---|---|---|---|
| Actual | $0.68 | $0.64 | $0.68 | $0.79 |
| Expected | $0.54 | $0.48 | $0.30 | $0.64 |
| Surprise | 25.93% | 33.33% | 128.19% | 23.44% |
| Beat | Beat | Beat | Current |
Financial Performance
| Q4 • 25 | Q1 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $153M | $149M | -2.11% |
| Net income | $52.7M | $63.7M | 20.94% |
| Profit margin | 34.53% | 42.66% | 23.55% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Catalyst Pharmaceuticals Inc share?
Catalyst Pharmaceuticals Inc shares are currently traded for undefined per share.
02How many shares does Catalyst Pharmaceuticals Inc have?
Catalyst Pharmaceuticals Inc currently has 122M shares.
03Does Catalyst Pharmaceuticals Inc pay dividends?
No, Catalyst Pharmaceuticals Inc doesn't pay dividends.
04What is Catalyst Pharmaceuticals Inc 52 week high?
Catalyst Pharmaceuticals Inc 52 week high is $32.56.
05What is Catalyst Pharmaceuticals Inc 52 week low?
Catalyst Pharmaceuticals Inc 52 week low is $19.05.
06What is the 200-day moving average of Catalyst Pharmaceuticals Inc?
Catalyst Pharmaceuticals Inc 200-day moving average is $25.41.
07Who is Catalyst Pharmaceuticals Inc CEO?
The CEO of Catalyst Pharmaceuticals Inc is Richard John Daly M.B.A..
08How many employees Catalyst Pharmaceuticals Inc has?
Catalyst Pharmaceuticals Inc has 182 employees.
09What is the market cap of Catalyst Pharmaceuticals Inc?
The market cap of Catalyst Pharmaceuticals Inc is $3.85B.
10What is the P/E of Catalyst Pharmaceuticals Inc?
The current P/E of Catalyst Pharmaceuticals Inc is 18.2.
11What is the EPS of Catalyst Pharmaceuticals Inc?
The EPS of Catalyst Pharmaceuticals Inc is $1.73.
12What is the PEG Ratio of Catalyst Pharmaceuticals Inc?
The PEG Ratio of Catalyst Pharmaceuticals Inc is 0.
13What do analysts say about Catalyst Pharmaceuticals Inc?
According to the analysts Catalyst Pharmaceuticals Inc is considered a buy.
